IBSA Group has established a commercial presence in the United States as IBSA Pharma Inc. and is planning to directly distribute Tirosint®, an FDA-approved treatment for hypothyroidism that it developed and previously distributed under license to another U.S.-based drug company.*  “IBSA has been present in the U.S. market with multiple products through third-party licensing agreements for several years,” said Aldo Donati, chief executive officer of IBSA Pharma. “The decision...